Drug Database
BE

benzodiazepine

✓ Approved

Valenta Pharm · 小分子 · 小分子

什么是 benzodiazepine?

benzodiazepine 是一种小分子,由Valenta Pharm研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

公司Valenta Pharm
药物类别小分子
给药途径Oral (PO)
状态Approved

治疗适应症

benzodiazepine 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Psychiatric disordersAnxiety✓ Approved

相关研究文献

PubMedExperimental animals2026-11-18

Flumazenil accelerates emergence from medetomidine-midazolam-butorphanol and dexmedetomidine-remimazolam-butorphanol anesthesia in mice.

Sasaki Takeru T, Watanabe Masaki M, Nakagawa Ryuya R, Ozaki Yui Y et al.

Injectable three-drug anesthesia in mice combines an α2-adrenoceptor agonist, a benzodiazepine and an opioid, as in the medetomidine-midazolam-butorphanol mixture and its newer variant, dexmedetomidine-remimazolam-butorphanol. Atipamezole, the usual reversal agent, antagonizes only the α2-adrenoceptor agonist, but does not directly reverse benzodiazepine-mediated activity. We examined whether adding the benzodiazepine antagonist flumazenil to atipamezole hastens emergence and alters post-anesthetic body temperature. Male C57BL/6JJcl mice received one of the two mixtures intraperitoneally and, 40 min later, atipamezole alone or with flumazenil (0.5 mg/kg each) in a 2 × 2 factorial design (n=6 per group). Flumazenil shortened the interval from antagonist administration to return of the righting reflex (RORR) by 4.54 min (95% CI, 1.93-7.15; P=0.002), with no anesthetic × antagonist interaction (P=0.62), although the study was not powered to establish equivalent effects between mixtures. Flumazenil approximately halved the temperature decline before RORR (P<0.001) without a detectable change in cooling rate (P=0.18), a pattern consistent with less time spent cooling rather than improved thermoregulation. Active warming was discontinued at antagonist administration in all groups, so the additional benefit under continued warming remains unknown. Later in recovery, temperature differences reflected the anesthetic mixture rather than the antagonist, dexmedetomidine-remimazolam-butorphanol-treated mice being 1.73°C warmer at the interpolated 220-min point (P=0.003). Adjunctive flumazenil hastened emergence under the tested conditions but does not replace thermal support and monitoring during recovery.

PMID 43051883
阅读全文 →
PubMedIranian journal of pharmaceutical research : IJPR2026-11-18

Adjunct Low-Dose Dexmedetomidine for Sedation in Mechanically Ventilated Children: An Exploratory Randomized Trial.

Farrokhian Amir A, Forouzan Najmeh N, Mirrahimi Bahador B, Hashemi Seyyedeh Masumeh SM et al.

Effective sedation in the pediatric intensive care unit (PICU) is complicated by the adverse effects of benzodiazepines and opioids. Dexmedetomidine may provide a benzodiazepine-sparing alternative with distinct pharmacologic properties. We hypothesized that adjunct, fixed low-dose, no-bolus dexmedetomidine would reduce midazolam and fentanyl exposure per ventilator-day in mechanically ventilated children. In a triple-blind randomized controlled trial, 60 mechanically ventilated patients aged 1 month to 12 years were randomized to standard sedation (continuous midazolam and fentanyl) plus low-dose dexmedetomidine (a fixed-rate continuous infusion at 0.2 µg/kg/h without a loading bolus) or matched placebo (0.9% normal saline). In both groups, midazolam and fentanyl were titrated per protocol to achieve the target Richmond Agitation-Sedation Scale (RASS) level. Among 60 randomized children, adjunct fixed low-dose dexmedetomidine did not reduce the prespecified primary outcome of fentanyl or midazolam exposure per ventilator-day. Median fentanyl exposure per ventilator-day was 70.0 µg·kg-1·day-1 in the control group and 90.6 µg·kg-1·day-1 in the dexmedetomidine group; median midazolam exposure per ventilator-day was 7.0 mg·kg-1·day-1 and 9.1 mg·kg-1·day-1, respectively. Neither primary comparison remained statistically significant after Holm correction. In an unadjusted secondary analysis, the median time to first successful extubation was 6 days in the dexmedetomidine group and 15 days in the control group. This finding was exploratory and was not confirmed by the prespecified competing-risk or longitudinal ventilation analyses. Adjunct fixed low-dose dexmedetomidine without a loading bolus did not reduce fentanyl or midazolam exposure per ventilator-day. Early sedative-analgesic exposure was higher with dexmedetomidine, and the apparent early-extubation signal was exploratory and was not confirmed by competing-risk or longitudinal analyses of ventilation.

PMID 43047987
阅读全文 →
PubMedAddiction (Abingdon, England)2026-11-17

'Can I keep myself safe?' in a system lacking support: A qualitative study on overdose risk perceptions by people who co-use benzodiazepine receptor agonists and opioids.

Vojt Gabriele G, Poulter Hannah H, Family Hannah E HE, Harris Neve N et al.

Co-use of benzodiazepines and z-drugs [collectively termed benzodiazepine receptor agonists (BZRA)] with opioids is involved in a large proportion of drug-related deaths. Historical and contemporary service provision rarely address the intersection between sociologically inherited disadvantage and current unmet treatment needs in people who use drugs. In this qualitative study, we examined people's understandings of overdose risk and what strategies, if any, they implemented to keep themselves safe when co-using BZRAs and opioids. We interviewed 48 people (37 men and 11 women) in community settings who co-use BZRAs and opioids (currently and up to 6 months before the study) in Bristol, Teesside and Glasgow, United Kingdom. We used a semi-structured topic guide to facilitate in-depth exploration of the ways in which people who co-use managed the risks of an overdose and other drug-related harms. Conceptually, we used the socioecological framework to develop the interview topic guide and frame the analysis and interpretation. All data were transcribed and analysed using reflexive thematic analysis. Intrapersonally, people were aware of the risks associated with co-using ('consumption roulette'), especially with illicitly obtained drugs. They tended to interrogate their ability to reduce the risk of overdosing within their social, physical and environmental context ('can I keep myself safe?'). At the intrapersonal level, for those higher in self-efficacy and agency, there was a sense of 'I can keep myself safe' by implementing tried-and-tested risk minimisation strategies, e.g. consuming drugs in small batches. However, among those lower in self-efficacy and agency, feelings of hope- and helplessness resulted in a belief that 'there is nothing you can do'. These narratives related back to participants' perception that system and service-level support was insufficient or lacking altogether ('they don't care about us'). We developed an explanatory self-regulatory model of co-use of benzodiazepine receptor agonists, opioids and risk. Co-use is driven partly by people's attempts to self-medicate, feel normal and function. Negative experiences (e.g. non-fatal overdose) caused most individuals to reconsider risk taking, with some expressing agency and implementing risk minimisation strategies while others felt disempowered by the wider system and the perceived lack of support and care. This lack of systemic support requires people to balance their needs to function against the risks of co-using by themselves.

PMID 43040973
阅读全文 →
PubMedBritish journal of clinical pharmacology2026-11-16

Measuring safer benzodiazepine deprescribing beyond prescription counts.

Singh Mhaveer M, Goyal Shefali S, Jayswal Jharilal Prasad JP, Jayaswal Rajesh Prasad RP

PMID 43035325
阅读全文 →
PubMedDrug metabolism and personalized therapy2026-11-16

Prospective genotype-guided drug selection and dosing in alcohol withdrawal syndrome complicated by seizures: a randomized clinical trial.

Skryabin Valentin Yu VY, Sokolova Svetlana I SI, Ivanchenko Valentina A VA, Matskevich Alla A AA et al.

To determine whether prospective genotype-guided drug selection and dosing can reduce cumulative withdrawal severity and improve treatment tolerability in alcohol withdrawal syndrome (AWS) complicated by seizures. In this single-center, parallel-group randomized clinical trial, 100 inpatients with AWS and seizures were allocated 1:1 to a genotype-guided prescribing strategy or control. All patients were genotyped on admission for CYP2D6*4, CYP2C19*2, CYP2C19*17, CYP3A4*1B, CYP3A5*3, and ABCB1 3435C>T. Intervention-group physicians received an individualized report with recommendations on benzodiazepine and anticonvulsant selection and starting dose; control-group physicians received a format-matched report without individualized recommendations. The primary outcome was area under the CIWA-Ar curve over 0-72 h, assessed by a blinded rater. AUC CIWA-Ar was 774.3 ± 175.9 vs. 903.6 ± 199.5 score-hours (mean difference -129.3; 95 % CI -204.0 to -54.6; p<0.001). Confirmed stabilization by 48 h occurred in 31/50 vs. 20/50 patients (log-rank p=0.020; Benjamini-Hochberg-adjusted p=0.051, not significant after multiplicity correction). UKU side-effect scores were lower on days 3 and 5 (both p<0.001), and excessive sedation occurred in 1/50 vs. 9/50 patients (p=0.016). Total benzodiazepine load was lower with genotype guidance (25.0 vs. 27.5 mg diazepam equivalents; p=0.016). The composite rate of clinically significant adverse events and the rates of delirium and unplanned treatment modification did not differ significantly. A prospective genotype-informed prescribing strategy was associated with lower cumulative withdrawal severity and less excessive sedation while using a lower benzodiazepine load. Because the intervention also changed anticonvulsant selection and drug concentrations were not measured, these findings support the clinical strategy as a whole rather than any single genotype-to-dose rule. Multicenter, prospectively registered trials with measured drug exposure are warranted.

PMID 43037191
阅读全文 →
PubMedOral and maxillofacial surgery2026-11-16

Impact of concomitant benzodiazepine receptor agonist and antidepressant use on the incidence of postoperative delirium after head and neck tumor surgery.

Schua Nathalie N, Nobis Christopher-Philipp CP, Oetter Nicolai N, Berger Melina M et al.

Postoperative delirium (POD) occurs after oncologic head and neck surgery with an incidence of 18,95%, and is with 25,43% even higher in patients with oral cancer. It also rises significantly with prolonged surgery duration > 6 h. Due to overlapping risk factors of POD and oral squamous cell carcinoma, patients undergoing head and neck cancer surgery are at increased risk for POD. The objective of our study was to evaluate the influence of a pre-existing concomitant medication with benzodiazepines receptor agonists (BZARs) or antidepressants on the risk for POD. This retrospective analysis was drawn with data from the Department of Oral and Maxillofacial Surgery of the University Hospital Erlangen. Included in the study were patients who underwent tumor resection and immediate microvascular reconstruction in between 2021 and 2024. The influence of BZARs and antidepressants on the incidence of POD was examined using logistic regression models. Age ≥ 70 was the only statistically significant risk factor (aOR 5.38, 95% CI: 2.18-13.30, p < 0.001). Concomitant medication with BZARs showed no relevant influence on POD intervals (aOR 2.11, 95% CI: 0.40-11.17, p = 0.38), in an unadjusted analysis an association between concomitant use of antidepressants and POD could be assumed, despite not reaching statistical significance in adjusted analysis (aOR 1.64, 95% CI 0.53-5.1, p = 0.39). The current body of evidence on the influence of BZARs on POD is highly heterogeneous in the literature and the overall level of evidence remains low. Concomitant BZAR use was not significantly associated with POD in the present study. Concomitant use of antidepressants was associated with POD in the univariable analysis, suggesting a potential clinical relevance; however, this association was not confirmed in the multivariable analysis. Age ≥ 70 is a significant risk factor for POD.

PMID 43035512
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多benzodiazepine